Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...
JPMorgan lowered the firm’s price target on Vistra (VST) to $186 from $203 and keeps an Overweight rating on the shares. The firm says that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback